BIOFLOW-SV All Comers Registry
NCT03600948 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 261
Last updated 2024-02-15
Summary
Assessment of the clinical safety and performance of the Orsiro drug-eluting stent in a real world setting in patients with small vessels with reference vessel diameter ≤2.75 mm.
Conditions
- de Novo
- Symptomatic Ischemic Heart Disease
- Restenoses, Coronary
Interventions
- DEVICE
-
Orsiro Sirolimus Eluting Coronary Stent System
Percutaneous coronary intervention
Sponsors & Collaborators
-
Biotronik AG
lead INDUSTRY
Principal Investigators
-
Marco Weinstain, MD · Moinhos de Vento Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-08-27
- Primary Completion
- 2020-08-31
- Completion
- 2021-10-06
Countries
- Brazil
Study Locations
More Related Trials
-
BIOFLOW III Satellite-ELADIS Orsiro Stent System
NCT02029092 ·Status: COMPLETED
-
BIOFLOW-III Israel Satellite Registry
NCT01895712 ·Status: COMPLETED
-
Prospective, Randomized, Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus-eluting Stent
NCT01939249 ·Status: UNKNOWN ·Phase: NA
-
Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
NCT02389946 ·Status: COMPLETED ·Phase: NA
-
BIOFLOW-III Canada Satellite Registry
NCT01880242 ·Status: COMPLETED
-
Post-marketing Registry of Inspiron Sirolimus Eluting Coronary Stent
NCT03263260 ·Status: COMPLETED
-
BIOFLOW-III Austria Satellite Registry
NCT01667016 ·Status: COMPLETED
-
BIOFLOW III Satellite-Italy Orsiro Stent System
NCT02028728 ·Status: COMPLETED
-
BIOTRONIK Orsiro Pre-Marketing Registration
NCT02870985 ·Status: COMPLETED ·Phase: NA
-
BIOFLOW III Asia Registry Orsiro Stent System
NCT01941290 ·Status: COMPLETED
-
Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
NCT04175626 ·Status: COMPLETED
-
BIOFLOW-INDIA Safety and Clinical PerFormance of the Drug Eluting ORSIRO Stent in Single de Novo Coronary Artery Lesions
NCT01426139 ·Status: COMPLETED ·Phase: NA
-
Study of the Orsiro Drug Eluting Stent System
NCT01356888 ·Status: UNKNOWN ·Phase: NA
-
Brazil Xience V Everolimus-Eluting Coronary Stent System "Real-World" Outcomes Registry
NCT00989066 ·Status: COMPLETED
-
BIOFLOW-china Post-marketing Study (BIOTRONIK)
NCT05667285 ·Status: TERMINATED
-
Comparison of Biodegradable Stents: Orsiro and BioMatrix
NCT02084901 ·Status: COMPLETED ·Phase: PHASE4
-
Post-Market Registry to Evaluate the Safety and Efficacy of the The SUPRAFLEX CRUZ™ Sirolimus Eluting Coronary Stent System in the Treatment of an Octo- and Nonagenerian All-Comer Patient Cohort With Coronary Artery Disease - the Cruz Senior Study
NCT04612179 ·Status: COMPLETED
-
Latin America Real World Study With Inspiron Drug Eluting Stent - INSPIRON LATITUDE
NCT03471234 ·Status: COMPLETED
-
Comparison of Biomatrix and Orsiro Drug Eluting Stent
NCT02299011 ·Status: COMPLETED ·Phase: PHASE4
-
The E-SERIES Registry for Supralimus® Coronary Stent for the Treatment of Unselected Patients With Coronary Lesions
NCT01368627 ·Status: COMPLETED ·Phase: PHASE4
-
Sirolimus-eluting Stents With Biodegradable Polymer Versus an Everolimus-eluting Stents
NCT01443104 ·Status: COMPLETED ·Phase: NA
-
Coroflex® ISAR NEO PMCF Study
NCT05698732 ·Status: RECRUITING
-
Everolimus-eluting SYNERGY Stent Versus Biolimus-eluting Biomatrix NeoFlex Stent - SORT-OUT VIII
NCT02093845 ·Status: UNKNOWN ·Phase: NA
-
Clinical Performance of the Pantera Lux Balloon Versus the Orsiro Stent in Patients With In-stent Restenosis.
NCT01651390 ·Status: COMPLETED ·Phase: NA
-
FIM-BR - First-in-Man Study (Brazil Part) With Sirolimus-Coated BX VELOCITY Stent
NCT00233792 ·Status: COMPLETED ·Phase: PHASE1/PHASE2